Share this Page:
The first patient has been dosed in the TiNivo trial: a Phase I/II clinical trial investigating tivozanib, a VEGF tyrosine kinase inhibitor, in combination with the immunotherapy, nivolumab in people with advanced renal cell carcinoma (RCC). The trial is to be led by the Institut Gustave Roussy in Paris under the direction of Professor Bernard Escudier, chairman of the Genitourinary Oncology Committee.
The phase I part of the TiNivo trial will assess the optimal dose of each drug to be used in the combination, and will then be expanded into a phase II trial using the combination dose.
